Bone Biologics
369 South Doheny Drive
Suite 1201
Beverly Hills
California
90211
United States
Tel: 818-324-2742
Fax: 310-385-8305
Website: http://www.bonebiologics.com/
Email: contact@bonebiologics.com
44 articles about Bone Biologics
-
Bone Biologics Announces Closing of $2.0 Million Public Offering
3/6/2024
Bone Biologics Corporation announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share and accompanying warrant.
-
Bone Biologics Announces Pricing of $2.0 Million Public Offering
3/4/2024
Bone Biologics Corporation today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock.
-
Bone Biologics Reports Progress With NB1 Clinical Program
3/1/2024
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.
-
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
1/11/2024
Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.
-
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
1/10/2024
Bone Biologics Corporation today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
-
Bone Biologics Announces 1-for-8 Reverse Stock Split
12/18/2023
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.
-
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11/20/2023
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share.
-
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - November 16, 2023
11/16/2023
Bone Biologics Corporation announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules.
-
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
9/26/2023
Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
-
Bone Biologics Prices $5.0 Million Underwritten Public Offering
6/15/2023
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the pricing of an underwritten public offering of common stock.
-
Bone Biologics Effects 1-for-30 Reverse Stock Split
6/6/2023
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on June 7, 2023.
-
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
4/11/2023
Bone Biologics Corporation announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.
-
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
1/26/2023
Bone Biologics Corporation announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1.
-
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
10/12/2022
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Bone Biologics Prices $5,100,000 Million Underwritten Public Offering
10/7/2022
Bone Biologics Corporation announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
3/7/2022
Bone Biologics Corporation announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM).
-
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
1/5/2022
Bone Biologics Corporation announced that Jeffrey Frelick, the Company’s president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 – 13, 2022.
-
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
10/18/2021
Bone Biologics Corp. today announced that it closed a public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
10/13/2021
Bone Biologics Corp., a developer of orthobiologic products for spine fusion markets, announced the pricing of its underwritten public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
1/7/2020
Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.